All In Biotech

Drug Trial Radar · NCT04136184

NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Last checked: Nov 20, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

168

Actual

Start

Dec 11, 2019

Primary completion

Apr 11, 2023

Study completion Jul 12, 2023

Sponsor

Lead sponsor
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
Sponsor type
Industry
First posted
Oct 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 82 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study was to evaluate the efficacy of eplontersen as compared with the historical control of the placebo cohort in the NEURO-TTR trial (NCT01737398/2012-001831-30), in subjects with hereditary transthyretin-mediated amyloidosis polyneuropathy (hATTR-PN). For more information, please visit http://www.neuro-ttransform.com/.

Conditions

  • Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Interventions

  • InotersenDrug

    Inotersen by subcutaneous injection

  • EplontersenDrug

    Eplontersen by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Modified Neuropathy Impairment Score Plus 7 (mNIS+7) at Week 66Time frame: Baseline, Week 66
  2. Change From Baseline in the Norfolk Quality of Life Diabetic Neuropathy (QoL-DN) Questionnaire at Week 66Time frame: Baseline, Week 66
  3. Percent Change From Baseline in Serum TTR Concentration at Week 65Time frame: Baseline, Week 65
  4. Percent Change From Baseline in Serum TTR Concentration at Week 35Time frame: Baseline, Week 35
  5. Change From Baseline in Modified Neuropathy Impairment Score Plus 7 (mNIS+7) at Week 35Time frame: Baseline, Week 35

Locations

45 sites in 16 countries. Site status is shown where the registry gives one.

  • Mayo Clinic - Arizona

    Scottsdale, Arizona

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida

  • Indiana University School of Medicine - Indianapolis

    Indianapolis, Indiana

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Johns Hopkins University Neurology Research Office

    Baltimore, Maryland

  • Boston University School of Medicine

    Boston, Massachusetts

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • The Neurological Institute of New York

    New York, New York

  • University of North Carolina Hospitals - Neurology Clinic

    Chapel Hill, North Carolina

  • Oregon Health and Science University

    Portland, Oregon

  • Penn Presbyterian Medical Center

    Philadelphia, Pennsylvania

  • University of Washington Medical Center

    Seattle, Washington

  • STAT Research

    Buenos Aires, Argentina

  • Instituto Fleni

    Buenos Aires, Argentina

  • Hospital Italiano de Buenos Aires

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Hospital El Cruce

    San Juan Bautista, Buenos Aires, Argentina

  • Perron Institute for Neurological and Translational Science

    Nedlands, Western Australia, Australia

  • Universidade Estadual de Campinas

    Campinas, Brazil

  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto

    Ribeirão Preto, Brazil

  • Hospital Universitário Clementino Fraga Filho

    Rio de Janeiro, Brazil

  • Associação de Assistência à Criança Deficiente - Unidade Lar Escola

    São Paulo, Brazil

  • Instituto de Neurologia de Curitiba

    Curitiba, Paraná, Brazil

  • Toronto General Hospital

    Toronto, Ontario, Canada

  • The Cyprus Institute of Neurology and Genetics

    Égkomi, Cyprus

  • Hôpital de la Timone

    Marseille, France

  • Centre Hospitalier Universitaire de Toulouse

    Toulouse, Haute-Garonne, France

  • Hôpital Bicêtre

    Le Kremlin-Bicêtre, Île-de-France Region, France

  • Universitätsklinikum Heidelberg

    Heidelberg, Germany

  • Universitätsklinikum Würzburg

    Würzburg, Bavaria, Germany

  • University General Hospital of Heraklion (PAGNI)

    Heraklion, Crete, Greece

  • Azienda Ospedaliera Universitaria Policlinico Gaetano Martino

    Messina, Italy

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan, Italy

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli

    Roma, Italy

  • Auckland City Hospital

    Grafton, Auckland, New Zealand

  • Centro Hospitalar Universitário Lisboa Norte - Hospital De Santa Maria

    Lisbon, Portugal

  • Centro Hospitalar Universitário do Porto - Hospital Geral de Santo Antonio

    Porto, Portugal

  • Hospital Clínico San Carlos

    Madrid, Spain

  • Hospital Son Llàtzer

    Palma de Mallorca, Balearic Islands, Spain

  • Norrlands Universitetssjukhus

    Umeå, Sweden

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.